articleTop 1% cited

Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy

European Journal of Cancer · 1993 · Vol. 29(3) · pp. 319–324

V. Trillet-Lenoir✉(Hôpital Louis Pradel)J. GreenC. Manegold(Frauenklinik Heidelberg)Joachim von Pawel(Asklepios Fachkliniken München-Gauting)U. Gatzemeier(LungenClinic Grosshansdorf)B Lebeau(Hôpital Saint-Antoine)A DepierrePeter JohnsonGenevieve Decoster(Roche (Switzerland))Dianne TomitaC. Ewen

View via DOI Publisher page

Neutropenia and Cancer Infections Oral health in cancer treatment Hematological disorders and diagnosticsGranulocyte colony-stimulating factorRecombinant DNACytotoxic T cellGranulocyteChemotherapyMedicineImmunologyCancer researchMicrobiologyInternal medicine

MeSH terms

Antineoplastic Combined Chemotherapy ProtocolsBacterial InfectionsCyclophosphamideDouble-Blind MethodDoxorubicinEtoposideFemaleHumansLung NeoplasmsMaleMiddle AgedNeutropeniaRecombinant ProteinsGranulocyte Colony-Stimulating FactorCarcinoma, Small Cell

Citations

545

FWCI

15.57

field-weighted impact

References

Percentile

99%

vs. same field & year

Citations per year

Cited by

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours